N. David Gill's Insider Trades & SAST Disclosures
N. David Gill's most recent trade in Evolus Inc was a trade of 11,146 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern N. David Gill.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Evolus Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 11,146 | 11,146 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 7,364 | 41,328 (0%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 14,545 | 14,545 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,495 | 5,825 (0%) | 0% | 0 | Common Stock | |
| Evolus Inc | David N. Gill | Director | Sale of securities on an exchange or to another person at price $ 12.60 per share. | 13 May 2024 | 6,718 | 33,964 (0%) | 0% | 12.6 | 84,654 | Common Stock |
| Evolus Inc | David N. Gill | Director | Sale of securities on an exchange or to another person at price $ 12.72 per share. | 13 May 2024 | 3,643 | 40,682 (0%) | 0% | 12.7 | 46,356 | Common Stock |
| Evolus Inc | N. David Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 9,377 | 9,377 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 6,464 | 44,325 (0%) | 0% | 0 | Common Stock | |
| Evolus Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 11,789 | 11,789 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 8,293 | 37,861 (0%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 16,000 | 16,000 | - | - | Non-Employee Stock Option (right to buy) | |
| Evolus Inc | David N. Gill | Director | Sale of securities on an exchange or to another person at price $ 13.10 per share. | 13 May 2022 | 5,313 | 34,568 (0%) | 0% | 13.1 | 69,584 | Common Stock |
| Evolus Inc | David N. Gill | Director | Sale of securities on an exchange or to another person at price $ 13.62 per share. | 13 May 2022 | 5,000 | 29,568 (0%) | 0% | 13.6 | 68,080 | Common Stock |
| Evolus Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 22,727 | 22,727 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 15,568 | 39,881 (0%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 16,000 | 16,000 | - | - | Non-Employee Stock Option (right to buy) | |
| Evolus Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 19,313 | 24,313 (0%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Sale of securities on an exchange or to another person at price $ 46.52 per share. | 19 Jan 2021 | 2,000 | 0 (0%) | 0% | 46.5 | 93,045 | Common Stock |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 2,000 | 24,000 | - | - | Non-Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.16 per share. | 19 Jan 2021 | 2,000 | 2,000 (0%) | 0% | 11.2 | 22,320 | Common Stock |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2020 | 2,000 | 26,000 | - | - | Non-Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.16 per share. | 18 Nov 2020 | 2,000 | 2,000 (0%) | 0% | 11.2 | 22,320 | Common Stock |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Sale of securities on an exchange or to another person at price $ 45.76 per share. | 18 Nov 2020 | 2,000 | 0 (0%) | 0% | 45.8 | 91,530 | Common Stock |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2020 | 4,000 | 28,000 | - | - | Non-Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 03 Nov 2020 | 4,000 | 0 (0%) | 0% | 45 | 180,000 | Common Stock |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.16 per share. | 03 Nov 2020 | 4,000 | 4,000 (0%) | 0% | 11.2 | 44,640 | Common Stock |
| Y-Mabs Therapeutics Inc | David N. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 16,000 | 16,000 | - | - | Non-Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges